Papillary thyroid cancer

Cancer facts and figures. Atlanta: American Cancer Society; 2000. Cady B, Rossi R: An expanded view of risk-group definition in differentiated thyroid carcinoma. Surgery 1988, 104:947–953. Hay ID, Grant CS, Taylor WF, McConahey WM: Ipsilateral lobectomy versus bilateral lobar resection in papillary thyroid carcinoma: a retrospective analysis of surgical outcome using a novel prognostic scoring system. Surgery 1987, 102:1088. Sanders LE, Cady B: Differentiated thyroid cancer: reexamination of risk groups and outcome of treatment. Arch Surg 1998, 133:419–425. Clark OH: Papillary thyroid carcinoma: rationale for total thyroidectomy. In Textbook of Endocrine Surgery. Edited by Clark OH, Duh QY. Philadelphia: WB Saunders; 1997:90–93. Hay ID, Grant CS, Bergstralh EJ, et al.: Unilateral total lobectomy. Is it sufficient surgical treatment for patients with AMES low-risk papillary thyroid carcinoma? Surgery 1998, 124:958–966. This recent study from the Mayo Clinic provides a thoughtful argument for near-total thyroidectomy for patients with low-risk papillary thyroid carcinoma in retrospectively studying a large number of patients (1685), for a long period of time (mean of 18 years). Samaan NA, Schultz PN, Hickey RC, et al.: The results of various modalities of treatment of well differentiated thyroid carcinoma: a retrospective review of 1599 patients. J Clin Endocrinol Metab. 1992, 75:714–720. Maxon HR, Smith HS: Radioiodine-131 in the diagnosis and treatment of metastatic well-differentiated thyroid cancer. Endocrinol Metab Clin North Am 1990, 19:685–718. McHenry CR, Rosen IB, Walfish PG: Prospective management of nodal metastases in differentiated thyroid cancer. Am J Surg 1991, 162:353–356. Wanebo H, Coburn M, Teates D, Cole B: Total thyroidectomy does not enhance disease control or survival even in high-risk patients with differentiated thyroid cancer. Ann Surg 1998, 227:912–921. This study provides an opposing argument to total thyroidectomy by showing no difference in recurrence or survival even in high-risk patients. Wanebo HJ, Andrews W, Kaiser DK: Thyroid cancer: some basic considerations. CA Cancer J Clin 1983, 33:87–93. Farrar WB, Cooperman M, James AG: Surgical management of papillary and follicular carcinoma of the thyroid. Ann Surg 1980, 192:701–709. Schroder DM, Chambors A, France CJ: Operative strategy for thyroid cancer: is total thyroidectomy worth the price? Cancer 1986, 58:2320–2330. Massin JP, Savoie JC, Garnier H, et al.: Pulmonary metastases in differentiated thyroid carcinoma: study of 58 cases with implications for the primary tumor treatment. Cancer 1984, 53:982–992. Schlumberger M, Tubiana M, DeVathaire F, et al.: Longterm results of treatment of 283 patients with lung and bone metastases from differentiated thyroid carcinoma. J Clin Endocrinol Metab 1995, 80:2946–2957. DeGroot LJ, Kaplan EL, McCormick M, Straus FH: Natural history, treatment, and course of papillary thyroid carcinoma. J Clin Endocrinol Metab 1990, 71:414–420. Mazzaferri EL, Young RL: Papillary thyroid carcinoma: a 10-year follow-up report of the impact of therapy in 576 patients. Am J Med 1981, 70:511–521. Mazzaferri EL, Jhiang SM: Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med 1994, 97:418–428. Taylor T, Specker B, Robbins J, et al.: Outcome after treatment of high-risk papillary and non-Hürthlecell follicular thyroid carcinoma. Ann Intern Med 1998, 129:622–627. This recent study comes from the National Thyroid Cancer Treatment Cooperative Study Registry which is a prospective, multicenter study using uniform criteria for stratification of patients. Shaha AR, Shah JP, Loree TR: Low-risk differentiated thyroid cancer: the need for selective treatment. Ann Surg Oncol 1997, 4:328–333. Sanders LE, Cady B: Differentiated thyroid cancer: reexamination of risk groups and outcome of treatment. Arch Surg 1998, 133:419–425. Clark OH: Total thyroidectomy: the treatment of choice for patients with differentiated thyroid cancer. Ann Surg 1982, 196:361–370. Scanlon EF, Kellogg JE, Winchester DP, Larson RH: The morbidity of total thyroidectomy. Arch Surg 1981, 116:568–571. Attie JN, Moskowitz GW, Margouleff D, Levy LM: Feasibility of total thyroidectomy in the treatment of thyroid carcinoma: postoperative radioactive iodine evaluation of 140 cases. Am J Surg 1979, 138:555–564. Thompson NW: Total thyroidectomy in the treatment of thyroid carcinoma. In Endocrine Surgery Update. Edited by Thompson NW, Vinik AI. New York: Grune & Stratton; 1983:71–84. Clark OH, Duh QY: Thyroid cancer. Med Clin North Am 1991, 75:211–242. Walker RP, Paloyan E, Kelley TF, et al.: Parathyroid autotransplantation in patients undergoing a total thyroidectomy: a review of 261 patients. Otolaryngol Head Neck Surg 1994, 111:258–264. Olson JA, DeBenedetti MK, Baumann DS, Wells SA: Parathyroid autotransplantation during hyroid-ectomy:results of long-term follow-up. Ann Surg 1996, 223–232. Russel WD, Ibanez ML, Clark RL, et al.: Thyroid carcinoma: classification, intraglandular dissemi-nation and clinicopathological study based upon whole organ sections of 80 glands. Cancer 1963, 11:1425–1437. Shaha A, Loree TR, Shah JP: Intermediate risk group for differentiated carcinoma of the thyroid. Surgery 1994, 116:1036–1041. Coburn MC, Wanebo HJ: Prognostic factors and management considerations in patients with cervical metastases of thyroid cancer. Am J Surg 1992, 164:671–676. Noguchi S, Murakami N: The value of lymph node dissection in patients with differentiated thyroid cancer. Surg Clin North Am 1987, 67:251–261. Noguchi S, Noguchi A, Murakami N: Papillary carcinoma of the thyroid: I. Developing pattern of metastasis. Cancer 1970, 26:1053–1060. Scheumann GFW, Grimm O, Wegener G, et al.: Prognostic significance and surgical management of locoregional lymph node metastases in papillary thyroid cancer. World J Surg 1994, 18:559–568. Hughes CJ, Shaha AR, Shah JP, et al.: Impact of lymph node metastasis in differentiated carcinoma of the thyroid: a matched pair analysis. Head Neck 1996, 18:127–132. Schelfhout LJDM, Creutzberg CL, Hamming JF, et al.: Multivariate analysis of survival in differentiated thyroid cancer: the prognostic significance of the age factor. Eur J Cancer Clin Oncol 1988, 24:331–337. Krishnamurthy GT, Blahd WH: Radioiodine I131 therapy in the management of thyroid carcinoma: a prospective study. Cancer 1977, 40:195–202. Mazzaferri EL: Thyroid remnant 131I ablation for papillary and follicular thyroid carcinoma. Thyroid 1997, 7:265–271. Morris DM, Boyle PJ, Stidley CA, et al.: Localized well-differentiated thyroid carcinoma: survival analysis of prognostic factors and (131)I therapy. Ann Surg Oncol 1998, 5:329–337. Tsang RW, Brierley JD, Simpson WJ, et al.: The effects of surgery, radioiodine, and external radiation therapy on the clinical outcome of patients with differentiated thyroid carcinoma. Cancer 1998, 82:375–388. Pelikan DMV, Lion HL, Hermans J, Goslings BM: The role of radioactive iodine in the treatment of advanced differentiated thyroid carcinoma. Clin Endocrinol 1997, 47:713–720. Tubiana M: External radiotherapy and radioiodine in the treatment of thyroid cancer. World J Surg 1981, 5:75–84. Schober O, Gunter HH, Schwarzrock R, et al.: Hamato-logische Langzeitveranderungen bei der Schilddrusen-karzinoms (German). Strahlenther Onkol 1987, 163:464. Ceccareli C, Pacini F, Lippi F, et al.: Thyroid cancer in children and adolescents. Surgery 1988, 104:1143. Edmonds CJ, Smith T: The long term hazard of the treatment of thyroid cancer with radioiodine. Br J Radiol 1986, 59:45. Miccoli P, Pacini F: Papillary and follicular carcinoma: surgical and radioiodine treatment of distant metastases. In Textbook of Endocrine Surgery. Edited by Clark OH, Duh QY. Philadelphia: WB Saunders; 1997:119–125. Solomon BL, Wartofsky L, Burman KD: Current trends in the management of well differentiated papillary thyroid carcinoma. J Clin Endocrinol Metab 1996, 81:333–339. Mazzaferri EL: Papillary and follicular thyroid cancer: a selective approach to diagnosis and treatment. Annu Rev Med 1981, 32:73. Mazzaferri EL: Factors influencing prognosis and current therapy. Semin Oncol 1987, 14:315. Keating FR, Parker TW, Selby JB, et al.: Treatment of heart disease associated with myxedema. Prog Cardiovasc Dis 1961, 3:364–370. Zbar AP, O’Higgens NJ: Use and abuse of thyroid-stimu-lating hormone suppressive therapy in patients with nodular goiter and benign or malignant thyroid neo-plasms. In Textbook of Endocrine Surgery. Edited by Clark OH, Duh QY. Philadelphia: WB Saunders; 1997:54–68. Grant CS, Hay ID, Gough IR, et al.: Local recurrence in papillary thyroid carcinoma: is extent of surgical resection important? Surgery 1988, 104:954. Shimaoka K, Schoenfeld D, Dewys WD, et al.: A ran-domised trial of doxorubicin versus doxorubicin plus cis-platinum in patients with advanced thyroid carcinoma. Cancer 1985, 56:2155–2160. Gottlieb JA, Hill CS: Chemotherapy of thyroid cancer with adriamycin. N Engl J Med 1974, 290:193–197. Durie BG, Hellman D, Woolfenden JM: High risk thyroid cancer: prolonged survival with early multi-modality therapy. Cancer Clin Trials 1981, 4:67–73. Hoskin PJ, Harmer C: Chemotherapy for thyroid cancer. Radiother Oncol 1987, 10:187–194.